Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/190752
Title: Neuroimaging of rapid eye movement sleep behavior disorder and its relation to Parkinson's disease
Author: Valli, Mikaeel
Uribe, Carme
Mihaescu, Alexander
Strafella, Antonio P.
Keywords: Malaltia de Parkinson
Trastorns del son
Imatges per ressonància magnètica
Tomografia per emissió de positrons
Tomografia computada per emissió de fotó simple
Parkinson's disease
Sleep disorders
Magnetic resonance imaging
Positron emission tomography
Single-photon emission computed tomography
Issue Date: 4-Jul-2022
Publisher: Wiley
Abstract: Rapid eye movement (REM) sleep behavior disorder (RBD) is a parasomnia characterized by polysomnography-confirmed REM sleep without atonia and dream-enacting behaviors. This disorder is considered a prodromal syndrome of alpha-synucleinopathies like Parkinson's disease (PD), where it affects more than 50% of PD patients. The underlying pathology of RBD has been generally understood to involve the pontine nuclei within the brainstem. However, the complete pathophysiology beyond the brainstem remains unclear as does its relationship with PD pathology. Therefore, this review aims to survey the neuroimaging literature involving PET, SPECT, and MR imaging techniques to provide an updated understanding of the neuro-chemical, structural, and functional changes in both RBD and PD patients comorbid with RBD. This review found neuroimaging evidence that indicate alterations to the dopaminergic and cholinergic system, blood perfusion, and glucose metabolism in both RBD patients and PD patients with RBD. Beyond the brainstem, structural and functional changes were found to involve the nigrostriatal system, limbic system, and the cortex-suggesting that RBD is a multi-systemic neurodegenerative process. Future investigations are encouraged to follow RBD patients longitudinally using multimodal imaging techniques to enhance our understanding of this parasomnia disorder. Uncovering which individuals are most likely to develop an alpha-synuclein disorder in the prodromal phase will improve patient outcomes and potentially aid in the development of novel treatments for patients affected by RBD.
Note: Versió postprint del document publicat a: https://doi.org/10.1002/jnr.25099
It is part of: Journal of Neuroscience Research, 2022, vol. 100, num. 10, p. 1815-1833
URI: http://hdl.handle.net/2445/190752
Related resource: https://doi.org/10.1002/jnr.25099
ISSN: 0360-4012
Appears in Collections:Articles publicats en revistes (Medicina)

Files in This Item:
File Description SizeFormat 
726679.pdf1.81 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.